3BFuture – 3BFuture Health Fund

A Bold Investment Strategy Focused on Building on Innovation

3B Future Health Fund supports US and European-based private early-stage, innovative companies in areas of high unmet patient needs.

Mission

Guided by our core values, inspired by the needs of patients and with a passion for science and oncology, we leverage our expertise and network to bring life-changing treatments to patients.
Vision

We strive to be the preferred partner to select investors and portfolio companies, motivated by a sense of purpose, excellent execution, personal involvement and premium performance.
Values

Looking for companies sharing our core values of QUALITY, INTEGRITY & RESPECT, and a strong passion for bringing new life-changing treatments to patients.

Investment Strategy

We focus on start-up companies based in Europe, the US and Israel. We support companies with potential first-in-class assets, revolutionary insights, experienced management teams and a strong investor syndicate. We typically make our initial investment in companies raising Series A rounds, but in some cases even earlier.

Learn more

Strategy

Team with proven track-record founded on robust due diligence and efficient work processes. Invests only in First Class Science & Technology.

Time Frame

10-year fund Investment in target companies to be held for five to eight years, or fewer if value inflection points are reached which could permit earlier exits.

Focus / Geography

100% healthcare, early stage and clinical development stage.

Therapeutic areas with strong unmet patient needs; priority on US and European-based startups focusing mainly on oncology and rare diseases, leveraging the expertise of the team.

Opportunistic investments, made on a case-by-case basis.

Portfolio Construction

Fund comprised of 10-15 companies, up to $12 million investment in each and Board position desirable.

We reserve capital for follow-on rounds.

Start-up Companies

Our team is building a diversified portfolio designed to balance the risks and optimise potential returns by investing in companies at early and mid-stages of development, with different levels of complexity in science and technology, drug modality agnostic and based across different geographies.

View our full portfolio